• Greenwich LifeSciences Inc (NASDAQ: GLSI) has announced the abstract results of the final 5-year immune response data of the Phase 2b trial at the 2021 AACR Annual Meeting.

• The company plans to publish the poster, the abstract, and an audio recording tomorrow in a joint press release.

• Potent immune response data, supports the previously reported clinical outcome of 0% metastatic breast cancer recurrences over five years of follow-up.

• A statistically significant peak immunity was reached after six months of GP2 treatment as measured in both a GP2 specific CD8 T cell dimer binding assay and a delayed-type-hypersensitivity (DTH) skin test.

• HER2 3+ population immune response was similar to the HER2 1-2+ population immune response, suggesting the potential to treat the HER2 1-2+ population with GP2 immunotherapy in combination with trastuzumab (Herceptin) based products and other clinically active agents.

• GP2 is immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.

• Price Action: GLSI shares are trading 15.8% higher at $58.5 in premarket trading on the last check Friday.

See more from Benzinga

• Click here for options trades from Benzinga

• Celcuity Stock Moves Higher After Licensing Pact With Pfizer For Gedatolisib In Breast Cancer

• Provention Bio Stock Craters After FDA Flags Deficiencies In PK Profiles From Teplizumab Trials For Diabetes

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.